======= NFKB2 =======
== Gene Information ==
* **Official Symbol**: NFKB2
* **Official Name**: nuclear factor kappa B subunit 2
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=4791|4791]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q00653|Q00653]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=NFKB2&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20NFKB2|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/164012|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: This gene encodes a subunit of the transcription factor complex nuclear factor-kappa-B (NFkB). The NFkB complex is expressed in numerous cell types and functions as a central activator of genes involved in inflammation and immune function. The protein encoded by this gene can function as both a transcriptional activator or repressor depending on its dimerization partner. The p100 full-length protein is co-translationally processed into a p52 active form. Chromosomal rearrangements and translocations of this locus have been observed in B cell lymphomas, some of which may result in the formation of fusion proteins. There is a pseudogene for this gene on chromosome 18. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2013].
* **UniProt Summary**: NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF- kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14- activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK- ARNTL/BMAL1 heterodimer. {ECO:0000269|PubMed:7925301}.
|Death|
|Ank 2|
|Ank|
|RHD|
|Bcl3/NF-kappaB2 complex|
|follicular dendritic cell differentiation|
|follicular dendritic cell activation|
|germinal center formation|
|spleen development|
|positive regulation of type I interferon production|
|NIK/NF-kappaB signaling|
|regulation of type I interferon production|
|positive regulation of NF-kappaB transcription factor activity|
|positive regulation of DNA-binding transcription factor activity|
|rhythmic process|
|aging|
|adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains|
|transcription coactivator activity|
|response to lipopolysaccharide|
|response to molecule of bacterial origin|
|extracellular matrix organization|
|extracellular structure organization|
|regulation of DNA-binding transcription factor activity|
|DNA-binding transcription activator activity, RNA polymerase II-specific|
|positive regulation of cytokine production|
|RNA polymerase II proximal promoter sequence-specific DNA binding|
|hematopoietic or lymphoid organ development|
|adaptive immune response|
|immune system development|
|DNA-binding transcription factor activity|
|response to bacterium|
|regulation of cytokine production|
|response to lipid|
|anatomical structure formation involved in morphogenesis|
|cell activation|
|response to cytokine|
|positive regulation of transcription by RNA polymerase II|
|response to other organism|
|response to external biotic stimulus|
|response to biotic stimulus|
|positive regulation of transcription, DNA-templated|
|response to oxygen-containing compound|
|DNA-binding transcription factor activity, RNA polymerase II-specific|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|intracellular signal transduction|
|positive regulation of RNA metabolic process|
|positive regulation of multicellular organismal process|
|positive regulation of molecular function|
|immune response|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|positive regulation of biosynthetic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp17|DABN 20μM R00 exp17]]|-2.35|
|[[:results:exp46|HMS-I1 1μM R01 exp46]]|-2.05|
|[[:results:exp116|AICAR 240μM R03 exp116]]|-1.81|
|[[:results:exp212|Phenformin 20μM R05 exp212]]|-1.78|
|[[:results:exp7|Bortezomib 0.05μM R00 exp7]]|-1.74|
|[[:results:exp508|NN-Dimethylsphingosine 2.5μM R08 exp508]]|-1.73|
|[[:results:exp279|D-Fructose 10000μM R06 exp279]]|2.26|
No correlation found to any other genes in chemogenomics.
Global Fraction of Cell Lines Where Essential: 6/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|2/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|3/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 4130
* **Expression level (log2 read counts)**: 4.48
{{:chemogenomics:nalm6 dist.png?nolink |}}